Model-Driven Hybrid AI Framework for End-to-End Autonomous Decision-Making in Drug Development
Lee, H.; Kang, H.; Jung, W.; Cho, H.; Goo, S.; Yun, H.-y.; Kim, M.-G.; CHAE, J.-w.; Park, S.-M.; Lee, S.; Kim, J. H.; Jung, S.
Show abstract
Decision-making in drug development spans heterogeneous stages from molecular design to clinical optimization, yet computer-aided workflows across stages remain fragmented, limiting traceability from evidence-derived clinical questions to simulation scenarios and decision endpoints. We present a model-driven hybrid AI framework for end-to-end decision support that treats PICO (Participants, Intervention, Comparison, Outcome) as a machine-actionable specification to define scenarios and align endpoints across modules. Given a PICO-defined clinical question and a drug SMILES, the framework infers PBPK-ready parameters from structure, generates exposure via mechanistic PBPK simulation, and links exposure outputs to clinic-facing therapeutic drug monitoring (TDM) decision support using an open-source NLME-based Clinical Pharmacokinetic Consultant Service (CPCS). We additionally implement an LLM-based PICO extraction layer to structure clinical abstracts into P/I/C/O elements for systematic evidence ingestion. Results include backbone verification for DTI-guided intrinsic clearance prediction under fold-error bounds and PBPK trajectory plausibility, and external validation of the hybrid AI-PBPK pipeline showing substantial dispersion for several endpoints. An input-controlled comparison between PhysioSim and PK-Sim on N = 9 drugs yields similarly degraded accuracy under identical AI-predicted inputs, suggesting upstream parameter quality as a dominant constraint. For evidence ingestion, prompting-only PICO extraction achieves F1 of 0.687 on EBM-NLP and 0.552 on TB-PICO. For clinical utility, CPCS improves TDM performance over a PKS baseline on phenobarbital and vancomycin, reducing MAPE by approximately 26-60% depending on configuration. Overall, the framework provides a modular, traceable blueprint linking evidence-defined questions to exposure simulation and TDM decision support while preserving mechanistic interpretability. Future work will integrate outcome-aligned time-to-event modeling and federated learning to close the PICO-to-outcome loop and improve parameter inference under multi-site governance.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Controlling astrocyte-mediated synaptic pruning signals for schizophrenia drug repurposing with Deep Graph Networks 93%
- Contrasting model mechanisms of alanine aminotransferase (ALT) release from damaged and necrotic hepatocytes as an example of general biomarker mechanisms 93%
- Causal reasoning over knowledge graphs leveraging drug-perturbed and disease-specific transcriptomic signatures for drug discovery 92%
Similar papers in this journal
- Simulating clinical trials for model-informed precision dosing: Using warfarin treatment as a use case 92%
- Physiologically based pharmacokinetic (PBPK) modeling of the role of CYP2D6 polymorphism for metabolic phenotyping with dextromethorphan 92%
- stormTB: A web-based simulator of a murine minimal-PBPK model for anti-tuberculosis treatments. 92%
Similar papers in this journal
- AnimalGAN: A Generative Adversarial Network Model Alternative to Animal Studies for Clinical Pathology Assessment 94%
- comboFM: leveraging multi-way interactions for systematic prediction of drug combination effects 93%
- First fully-automated AI/ML virtual screening cascade implemented at a drug discovery centre in Africa 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.